William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of Insmed stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $163.22, for a total transaction of $1,746,290.78. Following the completion of the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at $49,159,415.70. This represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

William Lewis also recently made the following trade(s):

• On Thursday, March 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.52, for a total transaction of $1,535,520.48.
• On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $146.03, for a total transaction of $1,562,374.97.
• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $150.97, for a total transaction of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The shares were sold at an average price of $147.79, for a total transaction of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total transaction of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total transaction of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $561,349.91.

Insmed Stock Down 0.4%

Insmed stock opened at $159.59 on Friday. Insmed, Inc. has a 1-year low of $61.48 and a 1-year high of $212.75. The firm has a market capitalization of $34.45 billion, a price-to-earnings ratio of -24.90 and a beta of 1.10. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The firm has a 50 day simple moving average of $150.51 and a 200 day simple moving average of $166.98.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. During the same quarter in the prior year, the firm posted ($1.32) earnings per share. The firm’s quarterly revenue was up 152.6% on a year-over-year basis. On average, analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Institutional Trading of Insmed

A number of hedge funds have recently made changes to their positions in INSM. CW Advisors LLC bought a new stake in shares of Insmed during the 2nd quarter worth $576,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Insmed by 65.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 263 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of Insmed by 80.8% during the 2nd quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company’s stock worth $4,770,000 after acquiring an additional 21,176 shares during the last quarter. Baird Financial Group Inc. bought a new stake in shares of Insmed during the 2nd quarter worth $2,589,000. Finally, Amundi lifted its holdings in shares of Insmed by 21,194.4% during the 2nd quarter. Amundi now owns 11,499 shares of the biopharmaceutical company’s stock worth $1,130,000 after acquiring an additional 11,445 shares during the last quarter.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Large institutional holders remain significant supporters — recent disclosures show additions/large stakes from Norges Bank, Vanguard, RTW and Artisan, which provides a stabilizing ownership base under the share-price pressure.
• Neutral Sentiment: CEO William Lewis sold 10,699 shares under a pre-arranged Rule 10b5-1 plan; sale is notable but pre-planned sales reduce the negative governance signal. InsiderTrades: CEO sale
• Neutral Sentiment: Billionaire Stan Druckenmiller has trimmed a past position in INSM; a trim by a prominent investor is informational but not necessarily a directional catalyst unless followed by larger selling. InsiderMonkey: Druckenmiller trim
• Neutral Sentiment: Company update on the Phase 2b CEDAR study says there were no new safety signals for brensocatib, which limits safety-related downside even though efficacy failed. PR Newswire: CEDAR clinical update
• Negative Sentiment: Insmed will discontinue development of brensocatib (Brinsupri) for hidradenitis suppurativa after the Phase 2b trial missed primary and secondary endpoints and placebo outperformed active — this removes a potential label/indication and reduces pipeline optionality. Reuters: Program discontinued
• Negative Sentiment: Market reaction included a trading halt and a sharp share decline on the news, signaling elevated near-term volatility and negative investor sentiment while analysts and the market re-price the company’s growth assumptions. Investing.com: Stock falls after trial miss

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Citigroup reissued an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. HC Wainwright raised their price target on shares of Insmed from $230.00 to $245.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Mizuho raised their price target on shares of Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Truist Financial set a $205.00 price target on shares of Insmed in a report on Monday, January 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $212.67.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.